Hepatocellular carcinoma (HCC) is one of the most common malignancies on a global scale, with an incidence of 20–150 cases per 100,000 population per year in some areas of Asia and Africa. It occurs much less frequently in Western Europe and the United States(1–5 cases per 100,000 population per year) (1). In a prospective study from Japan, liver cirrhosis, and viral hepatitis were implicated as risk factors for HCC, each carrying a 3-yr cumulative risk of 12.5 and 3.8%, respectively. The risk of HCC was increased almost sevenfold in patients with hepatitis B surface antigen (2) and fourfold in patients with hepatitis C antibody (3). Studies from Western Europe have confirmed a yearly incidence of 3–5% for HCC in patients with cirrhosis (4). HCC is the seventh most common form of cancer in men and the ninth most common in women worldwide (5). Each year there are 1 million new cases globally. The male prevalence is 3 times greater than female.
KeywordsHepatocellular Carcinoma Glycogen Storage Disease Percutaneous Ethanol Injection Hepatic Venous Pressure Gradient Alpha Fetoprotein
Unable to display preview. Download preview PDF.
- 1.Sherlock S, Dooley J. Diseases of the Liver and Biliary System. Blackwell Scientific Publications, Oxford, 1993, p. 503.Google Scholar
- 23.Kawata S, Yamasaki E, Nagase T. Long-term administration of pravastatin, a potent Hmg-Coa reductase inhibitor, prolongs survival of patients with advanced hepatocellular carcinoma: a randomized controlled trial. Hepatology 1996;24:245a (Abstract).Google Scholar